-+ 0.00%
-+ 0.00%
-+ 0.00%

Heidelberg Pharma sets Phase 2 dose for myeloma drug candidate HDP-101 in Phase 1 trial

PUBT·09/07/2026 07:00:03
Listen to the news
Heidelberg Pharma sets Phase 2 dose for myeloma drug candidate HDP-101 in Phase 1 trial
  • Heidelberg Pharma set new Phase I/IIa data for pamlectabart tismanitin (HDP-101) in relapsed or refractory multiple myeloma for presentation at IMS 2026.
  • Results will be presented in Glasgow on Sep. 23, 2026, in a poster session.
  • Phase I dose-escalation completed in April 2026, establishing the recommended Phase 2 dose for the ongoing Phase IIa stage.
  • Study update points to consistent clinical activity with a favorable safety profile in heavily pretreated patients, supporting continued development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2394648_en) on September 07, 2026, and is solely responsible for the information contained therein.